China's 12th VBP Round Targets RMB 60B Market as Genialis Launches BioBridge for Cross-Border Oncology

China’s government has initiated enterprise submissions for its 12th national Volume-Based Procurement (VBP) batch, placing an estimated RMB 60 billion (US$8.8 billion) market across 65 critical drug varieties and accelerating the mandatory substitution of off-patent originators with low-cost generics and biosimilars. The round, run by the National Healthcare Security Administration (NHSA) in June 2026, coincides with a record surge in Chinese biopharma out-licensing, which reached $137.7 billion in 2025 driven by 157 deals—nearly three times the transaction volume of 2024.

The latest VBP expansion targets blockbuster treatments in oncology, cardiovascular disease, and metabolic disorders. Prominent therapies facing steep price erosion include Pfizer and Astellas’ advanced prostate cancer drug Xtandi (enzalutamide), whose core patent expired on 29 March 2026, and Novartis’s chronic heart failure medication Entresto (sacubitril/valsartan), which generates annual Chinese sales of up to RMB 8 billion (US$1.2 billion). This expansion builds on historical rounds that systematically broke down complex biological markets: the 6th national round targeted insulin products, forcing average price cuts of 48% across 42 product variants, while regional and national expansions absorbed oncology biosimilars including bevacizumab and rituximab, enabling low-cost domestic alternatives to capture up to 80% of public hospital volume via mandated displacement.

Since its 2018 rollout, China's VBP framework has traded guaranteed public hospital market volumes for deep price slashes, saving the medical system over US$60 billion but turning the domestic generic and biosimilar market into a low-margin desert. However, data reveal the NHSA is shifting away from pure price destruction to protect supply chain stability. In the 11th VBP round, which concluded in late October 2025 with average price cuts of approximately 70%, authorities kept final winning bid prices strictly confidential for the first time to curb unsustainable price spiralling. For this 2026 procurement window, a refined ‘anchor point rule’ strips market share from ultra-low bidders while capping the highest prices at 1.8 times the baseline anchor. Beijing has also elevated compliance requirements, mandating extensive GMP histories and 24 months of domestic sales track records between June 2021 and June 2026.

These measures align with the State Council's updated regulatory framework issued on 31 December 2025, which explicitly encourages R&D innovation to reinforce drug safety, and landmark pricing guidelines establishing a dual-track pharmaceutical economy. Under the directive, mature generics and biosimilars face unchecked market competition via VBP, while patented, first-in-class assets receive premium ‘value-based pricing’ protections. Driven by this domestic margin compression, Chinese firms are aggressively prioritizing cross-border innovation, fuelling a record outbound biotech licensing surge.

As the 13 July 2026 enrolment deadline approaches, multinational giants and domestic generics firms are recalculating market exposure. Meanwhile, the global drug development landscape has shifted with many innovative oncology therapies now being discovered and clinically validated first in China before being licensed for development in North America and Europe. To address the biological and regulatory challenges of these East-to-West transactions, Genialis has launched Genialis™ BioBridge, a supermodel-powered platform designed to help pharmaceutical sponsors translate clinical results generated in Chinese patient populations into biomarker-ready assets for Western trials and regulatory submissions. Regulatory agencies including the U.S. Food & Drug Administration (FDA) and the European Medicines Agency (EMA) typically require evidence that therapeutic activity and biomarker performance remain robust across geographically diverse populations, and BioBridge was built to help sponsors answer that question before launching costly global development programs.

BioBridge is powered by the Genialis™ Supermodel, a large molecular model of cancer biology pre-trained on more than one billion RNA-sequencing data points from globally diverse patients. It uses clinical and molecular data to estimate responder populations in diverse global regions, allowing pharma sponsors to anticipate differences in efficacy signals from Chinese trial results. The platform works through four steps: harmonizing molecular data across clinical sites, platforms, and vendors; mapping patient samples into the Supermodel’s shared biological framework trained on globally diverse cancer datasets from partners including Tempus, Cancer Research UK, Academica Sinica (Taipei), Sidra Medicine (Qatar), and 4basecare (India); identifying and validating molecular predictors of response and resistance across patient populations; and deploying biomarker-driven patient stratification strategies to support clinical development, trial enrichment, and regulatory submissions. The Supermodel's capabilities are validated in published research: Uhlik et al. (Frontiers in Oncology, 2023) demonstrated that the Xerna™ TME Panel, an RNA-based biomarker built on Supermodel technology, classified tumor microenvironment biology robustly across a dozen cancer types. Genialis will be at BIO 2026 in San Diego, June 22–25, 2026, to meet with sponsors evaluating cross-population development challenges.